Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020496 · ClinicalTrials.gov registry record · Early Phase 1
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
A Early Phase 1 study of Skin Diseases, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05020496: Active Early Phase 1 study of Skin Diseases, sponsored by University of Alabama at Birmingham.
NCT05020496 is a Early Phase 1 study of Skin Diseases that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants, below the 205-participant average among 14 other Skin Diseases trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020496, a Early Phase 1 study of Skin Diseases, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.
Primary Outcome
Measurement of skin bifold thickness after application of DPCP in millimeter
Conditions Studied
Interventions
- DRUG Diphenylcyclopropenone (DPCP)
Study Locations (1)
Alabama
- Whitaker Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-10-01 |
| Phase | Early Phase 1 |
What the registry record for NCT05020496 still lists
NCT05020496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 205-participant average among 14 other Skin Diseases trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Diphenylcyclopropenone (DPCP) is the first listed.
NCT05020496 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05020496 about?
NCT05020496 is a clinical study titled "Trem-1 and Ultraviolet Radiation-induced Immune Suppression". The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.
What is the current status of trial NCT05020496?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2022-03-21. Estimated completion is 2026-10-01.
What conditions does trial NCT05020496 study?
This clinical trial studies the following conditions: Skin Diseases.
What interventions are being tested in trial NCT05020496?
The interventions under investigation include: Diphenylcyclopropenone (DPCP) (DRUG).
Who is sponsoring clinical trial NCT05020496?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020496 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05020496's enrollment target sits among peer trials
70 9th of 14 higher than 6 of 14 other Skin Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
RECRUITING · Early Phase 1
-
OCT Vibrography for Biomechanical Properties of Tissues
RECRUITING · NA
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RECRUITING · Phase 3
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI